These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35383486)

  • 41. Progression Rates of LR-2 and LR-3 Observations on MRI to Higher LI-RADS Categories in Patients at High Risk of Hepatocellular Carcinoma: A Retrospective Study.
    Ranathunga D; Osman H; Islam N; McInnes MDF; Munir J; van der Pol CB; Elfaal M; Walsh C
    AJR Am J Roentgenol; 2022 Mar; 218(3):462-470. PubMed ID: 34643108
    [No Abstract]   [Full Text] [Related]  

  • 42. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
    Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Cramp M; Jackson S; Ryder S; Price A; Stein K
    Health Technol Assess; 2007 Sep; 11(34):1-206. PubMed ID: 17767898
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rate of hepatocellular carcinoma diagnosis in cirrhotic patients with ultrasound-detected liver nodules.
    Franzè MS; Bottari A; Caloggero S; Pitrone A; Barbera A; Lembo T; Caccamo G; Cacciola I; Maimone S; Alibrandi A; Pitrone C; Squadrito G; Raimondo G; Saitta C
    Intern Emerg Med; 2021 Jun; 16(4):949-955. PubMed ID: 33111165
    [TBL] [Abstract][Full Text] [Related]  

  • 44. LI-RADS-CEUS - Proposal for a Contrast-Enhanced Ultrasound Algorithm for the Diagnosis of Hepatocellular Carcinoma in High-Risk Populations.
    Schellhaas B; Wildner D; Pfeifer L; Goertz RS; Hagel A; Neurath MF; Strobel D
    Ultraschall Med; 2016 Dec; 37(6):627-634. PubMed ID: 27486793
    [No Abstract]   [Full Text] [Related]  

  • 45. Diagnostic efficacy of the Liver Imaging-Reporting and Data System (LI-RADS) with CT imaging in categorising small nodules (10-20 mm) detected in the cirrhotic liver at screening ultrasound.
    Abd Alkhalik Basha M; Abd El Aziz El Sammak D; El Sammak AA
    Clin Radiol; 2017 Oct; 72(10):901.e1-901.e11. PubMed ID: 28673446
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Introduction to the Liver Imaging Reporting and Data System for Hepatocellular Carcinoma.
    Tang A; Singal AG; Mitchell DG; Hecht EM; Fowler KJ; Kulik L; Parikh ND; Kono Y; Sirlin CB
    Clin Gastroenterol Hepatol; 2019 Jun; 17(7):1228-1238. PubMed ID: 30326302
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Is There a Difference Between LI-RADS 3 to LI-RADS 5 Progression Assessment Using CT Versus MR? A Retrospective, Single-Center, Longitudinal Study of Patients Who Underwent 5082 Radiologic Examinations for Surveillance of Hepatocellular Carcinoma Over a 43-Month Period.
    Ojeda PI; Hannan LM; Mieloszyk RJ; Hall CS; Mileto A; Harris WP; Park JO; Baheti AD; Hippe DS; Bhargava P
    Curr Probl Diagn Radiol; 2022; 51(2):176-180. PubMed ID: 33980417
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predictors and Cumulative Frequency of Hepatocellular Carcinoma in High and Intermediate LI-RADS Lesions: A Cohort Study from a Canadian Academic Institution.
    Tang ES; Hall G; Yu D; Menard A; Hopman W; Nanji S
    Ann Surg Oncol; 2019 Aug; 26(8):2560-2567. PubMed ID: 31025229
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis.
    Simmons O; Fetzer DT; Yokoo T; Marrero JA; Yopp A; Kono Y; Parikh ND; Browning T; Singal AG
    Aliment Pharmacol Ther; 2017 Jan; 45(1):169-177. PubMed ID: 27862091
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of LI-RADS with other non-invasive liver MRI criteria and radiological opinion for diagnosing hepatocellular carcinoma in cirrhotic livers using gadoxetic acid with histopathological explant correlation.
    Clarke CGD; Albazaz R; Smith CR; Rowe I; Treanor D; Wyatt JI; Sheridan MB; Guthrie JA
    Clin Radiol; 2021 May; 76(5):333-341. PubMed ID: 33461746
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors.
    Fraum TJ; Cannella R; Ludwig DR; Tsai R; Naeem M; LeBlanc M; Salter A; Tsung A; Shetty AS; Borhani AA; Furlan A; Fowler KJ
    Eur Radiol; 2020 Feb; 30(2):996-1007. PubMed ID: 31654212
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma.
    Kim SY; An J; Lim YS; Han S; Lee JY; Byun JH; Won HJ; Lee SJ; Lee HC; Lee YS
    JAMA Oncol; 2017 Apr; 3(4):456-463. PubMed ID: 27657493
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018.
    Ludwig DR; Fraum TJ; Cannella R; Ballard DH; Tsai R; Naeem M; LeBlanc M; Salter A; Tsung A; Shetty AS; Borhani AA; Furlan A; Fowler KJ
    Abdom Radiol (NY); 2019 Jun; 44(6):2116-2132. PubMed ID: 30798397
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MR versus CEUS LI-RADS for Distinguishing Hepatocellular Carcinoma from other Hepatic Malignancies in High-Risk Patients.
    Huang Z; Zhou P; Li S; Li K
    Ultrasound Med Biol; 2021 May; 47(5):1244-1252. PubMed ID: 33610338
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of Contrast-Enhanced Ultrasound versus Contrast-Enhanced Magnetic Resonance Imaging for the Diagnosis of Focal Liver Lesions Using the Liver Imaging Reporting and Data System.
    Wang JY; Feng SY; Yi AJ; Zhu D; Xu JW; Li J; Cui XW; Dietrich CF
    Ultrasound Med Biol; 2020 May; 46(5):1216-1223. PubMed ID: 32115307
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?
    Yang J; Huang JY; Chen X; Ling WW; Luo Y; Shi YJ; Liu JB; Lu Q; Lyshchik A
    Eur Radiol; 2021 Aug; 31(8):6397-6405. PubMed ID: 33492470
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ultrasound surveillance for hepatocellular carcinoma: service evaluation of a radiology-led recall system in a tertiary-referral centre for liver diseases in the UK.
    Farrell C; Halpen A; Cross TJ; Richardson PD; Johnson P; Joekes EC
    Clin Radiol; 2017 Apr; 72(4):338.e11-338.e17. PubMed ID: 28041651
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Does a combined CT and MRI protocol enhance the diagnostic efficacy of LI-RADS in the categorization of hepatic observations? A prospective comparative study.
    Basha MAA; AlAzzazy MZ; Ahmed AF; Yousef HY; Shehata SM; El Sammak DAEA; Fathy T; Obaya AA; Abdelbary EH
    Eur Radiol; 2018 Jun; 28(6):2592-2603. PubMed ID: 29368164
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.
    Kierans AS; Song C; Gavlin A; Roudenko A; Lu L; Askin G; Hecht EM
    AJR Am J Roentgenol; 2020 Nov; 215(5):1085-1092. PubMed ID: 32877248
    [No Abstract]   [Full Text] [Related]  

  • 60. Prevalence and clinical significance of discordant LI-RADS
    Yokoo T; Singal AG; Diaz de Leon A; Ananthakrishnan L; Fetzer DT; Pedrosa I; Khatri G
    Abdom Radiol (NY); 2020 Jan; 45(1):177-187. PubMed ID: 31342103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.